Key clinical point:
Major finding: Of 12 patients treated to date, 7 have maintained complete responses for times ranging up to 19 months.
Study details: Report on a phase 1 study including 12 patients with relapsed/refractory non-Hodgkin lymphomas.
Disclosures: Dr. Hari reported disclosures related to Juno, Kite, Spectrum, Janssen, Takeda, Celgene, and BMS. Several study coauthors were employed by Lentigen Technology, a Miltenyi Biotec Company.
Shah NN et al. TCT 2019,.